Frederic Arnold
Overview
Explore the profile of Frederic Arnold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westermann L, Nolde J, Wiegel J, Buchler G, Arnold F, Welte T
Am J Nephrol
. 2025 Feb;
:1-15.
PMID: 40010320
Introduction: Maintaining renin-angiotensin-aldosterone system inhibition (RAASi) in advanced chronic kidney disease (CKD) to delay CKD progression is still controversial. This is due to potential side effects associated with RAASi, such...
2.
Grahammer F, Dumoulin B, Gulieva R, Wu H, Xu Y, Sulaimanov N, et al.
Kidney Int
. 2024 Sep;
106(5):856-869.
PMID: 39218392
Progression of cystic kidney disease has been linked to activation of the mTORC1 signaling pathway. Yet the utility of mTORC1 inhibitors to treat patients with polycystic kidney disease remains controversial...
3.
Arnold F, Kupferschmid L, Weissenborn P, Heldmann L, Hummel J, Zareba P, et al.
Cell Mol Immunol
. 2024 Jul;
21(9):1066-1081.
PMID: 38961265
Immune-mediated nephritis is a leading cause of acute kidney injury and chronic kidney disease. While the role of B cells and antibodies has been extensively investigated in the past, the...
4.
Arnold F, Kappes J, Rottmann F, Westermann L, Welte T
J Intern Med
. 2023 Nov;
295(2):206-215.
PMID: 37925625
Background: Diabetes mellitus is a major risk factor for the development of chronic kidney disease (CKD). There is limited data addressing the value of glycated hemoglobin (HbA1c) to predict renal...
5.
Westermann L, Rottmann F, Hug M, Staudacher D, Wobser R, Arnold F, et al.
BMC Nephrol
. 2023 Sep;
24(1):260.
PMID: 37661268
No abstract available.
6.
Westermann L, Rottmann F, Hug M, Staudacher D, Wobser R, Arnold F, et al.
BMC Nephrol
. 2023 Aug;
24(1):235.
PMID: 37563703
Background: Primary membranous nephropathy (PMN) frequently causes nephrotic syndrome and declining kidney function. Disease progression is likely modulated by patient-specific and therapy-associated factors awaiting characterization. These cofactors may facilitate identification...
7.
Welte T, Westermann L, Kappes J, Schramm M, Bemtgen X, Staudacher D, et al.
Arthritis Rheumatol
. 2023 Jun;
75(11):2045-2053.
PMID: 37276446
Objective: B-cell depletion using the anti-CD20 monoclonal antibody rituximab is a cornerstone in the therapeutic concept of multiple autoimmune diseases. B-cell depletion is associated with a higher risk for severe...
8.
Thelen B, Schipperges V, Knorlein P, Hummel J, Arnold F, Kupferschmid L, et al.
Front Immunol
. 2023 Feb;
14:1058267.
PMID: 36756120
The T-box transcription factors T-bet and Eomesodermin regulate type 1 immune responses in innate and adaptive lymphocytes. T-bet is widely expressed in the immune system but was initially identified as...
9.
Welte T, Arnold F, Westermann L, Rottmann F, Hug M, Neumann-Haefelin E, et al.
BMC Nephrol
. 2023 Jan;
24(1):8.
PMID: 36631797
Background: C3 Glomerulopathy (C3G) is a rare glomerular disease caused by dysregulation of the complement pathway. Based on its pathophysiology, treatment with the monoclonal antibody eculizumab targeting complement C5 may...
10.
Arnold F, Huzly D, Tanriver Y, Welte T
BMC Infect Dis
. 2022 Sep;
22(1):734.
PMID: 36104663
Background: Effective SARS-CoV-2 vaccination in patients receiving treatment with B-cell depleting agents is challenging. Information on vaccination responses in these patients are a valuable tool to develop efficient vaccination regimens....